Number of items: 4.
2026
Anderson, S. et al.
(2026)
Biologically adaptive radiotherapy for oropharyngeal Cancer (BARitOne): An R-IDEAL stage 2a-2b technical optimisation, feasibility, and safety study – Study protocol.
Clinical and Translational Radiation Oncology,
(doi: 10.1016/j.ctro.2026.101245)
(In Press)
2025
Tate, M. et al.
(2025)
Clinical effectiveness, safety and viral mutagenicity of oral favipiravir for COVID-19: results from a community-based, open-label, randomised, phase III trial.
Antimicrobial Agents and Chemotherapy, 69(8),
e0005425.
(doi: 10.1128/aac.00054-25)
(PMID:40552814)
2021
Tsim, S. et al.
(2021)
Serum proteomics and plasma fibulin-3 in differentiation of mesothelioma from asbestos-exposed controls and patients with other pleural diseases.
Journal of Thoracic Oncology, 16(10),
pp. 1705-1717.
(doi: 10.1016/j.jtho.2021.05.018)
(PMID:34116230)
(PMCID:PMC8514249)
2019
Hatton, M. Q.F. et al.
(2019)
Accelerated, dose escalated, sequential chemoradiotherapy in non-small-cell
lung cancer (ADSCaN): a protocol for a randomised phase II study.
BMJ Open, 9(1),
e019903.
(doi: 10.1136/bmjopen-2017-019903)
(PMID:30700475)
(PMCID:PMC6352760)
This list was generated on Sat Aug 8 22:44:58 2026 BST.
